This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.
This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.

UK real-world evidence for SIMPONI® (golimumab) for the treatment of Ulcerative Colitis (UC)

SIMPONI is indicated for treatment of moderately to severely active Ulcerative Colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6-mercaptopurine (6-MP) or azathioprine (AZA), or who are intolerant to or have medical contraindications for such therapies.1